Results 131 to 140 of about 530,471 (260)

WDFY4-dependent cross-presentation proceeds via a vacuolar antigen-processing route. [PDF]

Proc Natl Acad Sci U S A
Postoak JL, Koch A, Shan S, Ohara RA, Jo S, Chen J, Desai P, Ou F, Kraft M, Diamond MS, Kim S, Murphy TL, Murphy KM.   +12 more
europepmc   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Cross-presentation of dead cell-associated antigens shapes the neoantigenic landscape of tumor immunity. [PDF]

Nat Immunol
Lim KHJ, Schulz O, Lobon I, Castro-Dopico T, Zapata L, Giampazolias E, Frederico B, Castellanos CA, Buck MD, Stainier W, Chakravarty P, Kelly G, Rogers NC, Cardoso A, Lee S, Vash B, Maiocco S, Mehta R, Strid J, Turajlić S, Reis E Sousa C.   +20 more
europepmc   +1 more source

Enhancement of Immune Responses Elicited by Nanovaccines through a Cross-Presentation Pathway. [PDF]

Tissue Eng Regen Med, 2023
Kim CG, Lee JC, Ju DB, Kim SK, Yun CH, Cho CS.   +5 more
europepmc   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

HACC-TNF-α-VLP Nanoparticles Facilitate HSP90-Dependent Antigen Cross-Presentation to Enhance CD8⁺ T Cell and Mucosal Immunity Against Foot-and-Mouth Disease. [PDF]

Int J Nanomedicine
Lv L, Su Y, Chen S, Su W, Yin Y, Ning P, Liu S, Yuan W, Li L.   +8 more
europepmc   +1 more source

Recent progress in type 1 classical dendritic cell cross-presentation - cytosolic, vacuolar, or both? [PDF]

Curr Opin Immunol, 2023
Ohara RA, Murphy KM.
europepmc   +1 more source

MITF maintains genome stability in nonmelanocyte lineages

Molecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson   +13 more
wiley   +1 more source

Deficiency of lysosomal TMEM175 in myeloid macrophages exerts anti-tumor immunity via inflammasome and cross-presentation pathway. [PDF]

Nat Commun
Zhang Z, Li X, Lu T, Yang J, Han X, Bi Z, Luo J, Alu A, Hong W, Chen S, Chen L, Cheng Y, He X, Zhu C, Wang M, Li Q, Wang Y, Li L, Lei H, Lan J, Geng J, Wei Y, Wei X.   +22 more
europepmc   +1 more source

Sec22b and Stx4 Depletion Has No Major Effect on Cross-Presentation of PLGA Microsphere-Encapsulated Antigen and a Synthetic Long Peptide In Vitro. [PDF]

J Immunol, 2023
Tondeur EGM, Voerman JSA, Geleijnse MAA, van Hofwegen LS, van Krimpen A, Koerner J, Mishra G, Song Z, Schliehe C.   +8 more
europepmc   +1 more source